29 April 2022
Publication of Annual Report and Financial Statements for the Year ended 31 December 2021
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US – 29 April 2022, 23:00 CEST: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the publication of its Annual Report and Financial Statements for the Year ended 31 December 2021.
The Annual Report is attached below and also available in the Investors/Financial Reports and Presentations section.
Download the PDF of the Annual Report and Financial Statements for the Year ended 31 December 2021
Contacts
Acacia Pharma Group plc
Mike Bolinder, CEO
+44 1223 919760 / +1 317 505 1280
IR@acaciapharma.com
International Media
Frazer Hall, Mark Swallow, David Dible
MEDiSTRAVA Consulting
+44 20 7638 9571
acaciapharma@medistrava.com
Media in Belgium and the Netherlands
Chris Van Raemdonck
+32 499 58 55 31
chrisvanraemdonck@telenet.be
US Investors
LifeSci Advisors
Irina Koffler
+1 917-734-7387
ikoffler@lifesciadvisors.com